@article{oai:yamanashi.repo.nii.ac.jp:00002685,
 author = {Ohta, Masato and Satoh, Kaneo and Fukasawa, Isao and Hosokawa, Kazuya and Oonishi, Tomoko and Nakagomi, Junko and Ozaki, Yukio\r},
 issue = {1},
 journal = {山梨医科学雑誌, Yamanashi medical journal},
 month = {},
 note = {Introduction: Cilostazol inhibits phosphodiesterase, with resultant increase in intracellular cyclic AMP, leading to platelet inhibition, particularly in the presence of prostaglandin E1 (PGE1). This study aimed to establish a cilostazol monitoring assay, using whole blood samples.\r Methods: Platelet aggregation in the presence or absence of indicated concentrations of PGE1 were assessed using VerifyNowR, MultiplateR and Total Thrombus-formation Analysis System (T-TASR).\r Results: In the presence of added PGE1, cilostazol inhibited in vitro platelet aggregation of VerifyNow, with the aspirin test by 19% and the IIb/IIIa test by 44%, respectively. After a single oral uptake of cilostazol in healthy volunteers, cilostazol decreased platelet aggregation, with the IIb/IIIa test by 46% and with the P2Y12 test by 24%, respectively. Multiplate or T-TAS failed to detect cilostazol effi cacy both in vitro and ex vivo. VerifyNow IIb/IIIa tests were used to monitor cilostazol effi cacy on cerebral infarction patients. Compared with pre-therapy blood samples, those after cilostazol uptake showed signifi cant inhibition of platelet aggregation in the presence of 3 nM (37%) and 10 nM PGE1 (69%).\r Conclusion: The IIb/IIIa tests of VerifyNow in the presence of 10 nM PGE1 is the most suitable tool for monitoring assessing cilostazol.},
 pages = {27--37},
 title = {<Original article> Assessment of cilostazol inhibition using whole blood samples : comparison of three platelet function tests},
 volume = {32},
 year = {2017}
}